Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders

Details for Australian Patent Application No. 2008315746 (hide)

Owner AstraZeneca AB

Inventors Delouvrie, Benedicte; Winter, Jon James Gordon; Bower, Justin Fairfield; Lambert, Christine; Barlaam, Bernard Christophe; Fairley, Gary; Harris, Craig Steven; Ouvry, Gilles

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2008315746

PCT Pub. Number WO2009/053737

Priority 07305005.6 21.12.07 EP; 08305180.5 19.05.08 EP; 07301491.2 25.10.07 EP

Filing date 22 October 2008

Wipo publication date 30 April 2009

International Classifications

C07D 413/04 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/4427 (2006.01) - containing further heterocyclic ring systems

A61K 31/497 (2006.01)

A61P 35/00 (2006.01) Antineoplastic agents

C07D 413/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

C07D 417/14 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

13 May 2010 PCT application entered the National Phase

  PCT publication WO2009/053737 Priority application(s): WO2009/053737

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008315748-Method and computer system for automatically answering natural language questions

2008315740-Process for preparing Odesmethylvenlafaxine